Research goal
Inflammation & Anti-inflammatory Research
Covers compounds researched for their anti-inflammatory properties across multiple pathways, from NF-κB inhibition to cytokine modulation and tissue-level inflammation resolution.
Relevant Compounds
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | COX inhibition; NO pathway modulation; suppresses pro-inflammatory cytokines | Broad anti-inflammatory, gut and systemic healing | View profile → |
| TB-500 | Thymosin Beta-4 analogue | Actin sequestration reducing inflammatory cell migration; downregulates inflammatory cytokines | Systemic anti-inflammatory, tissue repair, recovery | View profile → |
| GHK-Cu | Copper tripeptide | Antioxidant gene expression; NF-κB regulation; suppresses TNF-α and IL-6 | Anti-inflammatory, skin repair, collagen synthesis | View profile → |
| KPV | α-MSH tripeptide | MC1R/MC3R agonism; NF-κB inhibition; direct suppression of IL-1β, TNF-α | Direct NF-κB inhibitor, gut and systemic anti-inflammatory | View profile → |
| Selank | Anxiolytic peptide | IL-6 and interferon modulation; neuroinflammation reduction | Neuroinflammation, cytokine normalisation | View profile → |
Research Context
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) functions as a master transcriptional regulator of the inflammatory response — when activated, it drives the expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and COX-2. Multiple compounds in this group suppress NF-κB activity through distinct upstream signals: KPV acts via melanocortin receptor-mediated inhibition of IκB kinase; GHK-Cu modulates NF-κB through antioxidant gene activation and direct gene expression regulation; BPC-157 suppresses pro-inflammatory signalling through COX inhibition and nitric oxide pathway effects. This convergence on NF-κB from different entry points is part of what makes the mechanistic rationale for combining these compounds coherent.
TNF-α, IL-1β, and IL-6 are the three cytokines most frequently targeted in anti-inflammatory research, as they represent the central amplification loop of the inflammatory cascade. TNF-α initiates and amplifies acute inflammation; IL-1β activates endothelial cells and sustains immune activation; IL-6 drives the acute-phase response and, in chronic elevation, contributes to systemic inflammatory disease states. Research across this compound group — BPC-157, TB-500, GHK-Cu, and KPV — has investigated potential suppression of one or more of these mediators through different mechanisms, suggesting broad cytokine profile modulation is possible across the group.
The distinction between acute and chronic inflammation is important in evaluating this compound group's relevance. Acute inflammation — as in wound healing, tissue injury, or post-surgical repair — is a necessary and time-limited biological process. The compounds here tend to support resolution of this process (reducing excessive or prolonged acute inflammation) rather than suppressing it entirely. In chronic inflammation contexts — colitis, neuroinflammation, systemic low-grade inflammation of ageing — the aim is attenuation of a sustained, pathological inflammatory state. Research has investigated most compounds in this group across both contexts, and their profiles differ between acute resolution and chronic attenuation applications.
Compound Notes
BPC-157
BPC-157 exhibits broad anti-inflammatory activity across multiple pathways, making it one of the more mechanistically versatile compounds in this research space. Research has investigated its potential role in COX inhibition (reducing prostaglandin-driven inflammation), modulation of the nitric oxide pathway (which has complex pro- and anti-inflammatory effects depending on context), and downregulation of pro-inflammatory cytokines in both gut and systemic models. Its anti-inflammatory profile is closely tied to its healing and mucosal repair effects, which are partly driven by resolution of the inflammatory environment in injured tissue. Reported side effects in research and anecdotal accounts include mild gastrointestinal changes and injection-site reactions.
TB-500
TB-500's anti-inflammatory mechanism is primarily structural: Thymosin Beta-4 sequesters G-actin, which reduces the cytoskeletal dynamics required for leucocyte migration into inflamed tissue — effectively reducing the delivery of pro-inflammatory immune cells to the site of injury or chronic inflammation. Beyond this actin-sequestration mechanism, TB-500 has been documented to downregulate pro-inflammatory cytokine expression systemically. This combination — reduced cellular infiltration plus cytokine suppression — gives TB-500 a profile relevant to both acute wound inflammation (where excessive leucocyte infiltration can impair repair) and chronic systemic inflammation.
GHK-Cu
GHK-Cu (Glycine-Histidine-Lysine copper complex) exerts anti-inflammatory effects primarily through two pathways: upregulation of antioxidant genes (SOD, catalase) that reduce the oxidative stress driving NF-κB activation, and direct modulation of gene expression — including suppression of TNF-α and IL-6 transcription. Its anti-inflammatory profile was initially characterised in the context of wound healing and skin repair, where it was observed to shift the inflammatory microenvironment toward resolution and tissue remodelling. Research has also investigated systemic GHK-Cu anti-inflammatory effects in ageing and chronic disease models, positioning it at the intersection of anti-inflammatory and longevity research.
KPV
KPV is arguably the most direct NF-κB inhibitor in this compound group. Via MC1R and MC3R agonism, it activates a signalling cascade that suppresses IκB kinase activity — the kinase responsible for releasing NF-κB from its inhibitor complex and allowing nuclear translocation. This results in direct suppression of IL-1β, TNF-α, and other NF-κB-dependent inflammatory mediators at the gene transcription level. KPV's oral bioavailability adds to its utility for gut-targeted anti-inflammatory applications, where local mucosal delivery is relevant. Its potency as a direct NF-κB inhibitor distinguishes it from the more indirect anti-inflammatory mechanisms of BPC-157, TB-500, and GHK-Cu.
Selank
Selank's anti-inflammatory profile is specific to the neuroinflammation context. Research has documented its effects on cytokine normalisation — particularly IL-6 and interferon-gamma — in stressed models, and its GABAergic modulation reduces excitotoxic stress that contributes to neuroinflammatory cascades. Unlike the other compounds in this group, Selank's anti-inflammatory mechanism is primarily relevant in the central nervous system and in stress-associated immune dysregulation, rather than in peripheral tissue or systemic chronic inflammation. It is included here because neuroinflammation is an increasingly recognised component of systemic inflammatory disease, but researchers should note its distinct focus compared to BPC-157, TB-500, GHK-Cu, and KPV.
Commonly Reported Combinations
Several documented stacks draw from this compound group and are relevant to inflammation research contexts:
Wolverine — BPC-157 + TB-500
The most commonly reported two-compound anti-inflammatory and recovery stack. BPC-157 contributes broad cytokine suppression and NO/COX pathway anti-inflammatory activity; TB-500 adds actin-sequestration-mediated reduction of leucocyte migration and systemic cytokine downregulation. Their mechanisms are distinct rather than redundant, supporting a rationale for combined use.
View Wolverine stack →GLOW — BPC-157 + TB-500 + GHK-Cu
Extends Wolverine with GHK-Cu, adding antioxidant gene activation and TNF-α/IL-6 suppression alongside collagen synthesis support. The addition of GHK-Cu broadens the anti-inflammatory coverage to include antioxidant-mediated NF-κB attenuation and provides a skin and connective tissue repair dimension.
View GLOW stack →KLOW — BPC-157 + TB-500 + GHK-Cu + KPV
The broadest anti-inflammatory coverage of the three stacks, adding KPV's direct NF-κB inhibition and oral gut delivery to the GLOW foundation. KLOW is particularly relevant for researchers focused on both systemic and gut-specific inflammation, as KPV contributes the only orally bioavailable compound in the stack with documented intestinal mucosal activity.
View KLOW stack →Frequently Asked Questions
What is NF-κB and why is it a primary target in anti-inflammatory peptide research?
NF-κB is a transcription factor that, when activated, translocates to the cell nucleus and drives transcription of a large number of pro-inflammatory genes — including those coding for TNF-α, IL-1β, IL-6, COX-2, and inducible nitric oxide synthase. It sits at the convergence point of multiple inflammatory signalling cascades triggered by infection, injury, oxidative stress, and immune activation. Because NF-κB controls the transcription of so many downstream inflammatory mediators simultaneously, inhibiting it at the transcriptional level is pharmacologically efficient: a single compound can suppress a broad array of inflammatory outputs. This is why multiple compounds in different chemical classes — KPV, GHK-Cu, BPC-157 — are all of interest in the context of NF-κB modulation, even though they arrive at that target through distinct receptor and signalling pathways.
Which compounds in this group are researched for acute inflammation vs chronic inflammation?
Most compounds in this group have preclinical evidence across both contexts, but their profiles differ. BPC-157 and TB-500 have strong acute models — wound healing, post-surgical repair, tendon and muscle injury — where their anti-inflammatory effects contribute to faster resolution and reduced fibrosis. GHK-Cu's profile spans acute wound healing (where its antioxidant and anti-inflammatory gene activation supports early repair) and chronic contexts (ageing-associated inflammation, systemic gene expression studies). KPV has been most specifically studied in chronic mucosal inflammation — IBD, colitis models — where sustained NF-κB suppression is the therapeutic target. Selank's research is focused primarily on chronic neuroinflammation and stress-associated cytokine dysregulation rather than acute tissue inflammation.
Is there research supporting combinations of multiple anti-inflammatory peptides, and what is the rationale for KLOW?
No controlled studies have formally evaluated combinations of the compounds in this group in anti-inflammatory contexts. The rationale for KLOW — and for combination approaches generally — is mechanistic complementarity: each compound targets different points in the inflammatory cascade, making overlapping coverage of multiple pathways theoretically more comprehensive than any single compound alone. BPC-157 (COX/NO pathways), TB-500 (cellular migration/actin), GHK-Cu (antioxidant/gene expression), and KPV (direct NF-κB) represent genuinely distinct entry points into inflammatory suppression rather than redundant activity at the same target. Whether this translates to additive or synergistic effects in practice is not validated by controlled research, and combination use carries compound interaction considerations not present in single-compound protocols.
How does Selank's anti-inflammatory mechanism differ from the other compounds in this group?
Selank's anti-inflammatory activity is primarily neuroinflammation-specific, operating through the stress-immune axis rather than through direct cytokine suppression or NF-κB inhibition in peripheral tissue. Its mechanisms include GABAergic modulation (reducing excitotoxic-driven neuroinflammation), cytokine normalisation in the CNS (IL-6, interferon-gamma), and reduction of stress-induced immune dysregulation. The other compounds in this group — BPC-157, TB-500, GHK-Cu, KPV — have established anti-inflammatory profiles in peripheral tissue and systemic contexts. Selank's relevance to this goal is most appropriate in neuroinflammation research contexts, or in protocols where the stress-immune-inflammation axis is the target, and it should not be substituted for the peripheral anti-inflammatory compounds in standard healing or systemic inflammation research contexts.